skip to main content

P1NP Monitoring Teriparatide — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateMetabolic Bone DiseaseP1NP Monitoring TeriparatideSCE Rheumatology

A 65-year-old woman with severe postmenopausal osteoporosis starts teriparatide 20 micrograms once daily after previously receiving alendronate. Her serum P1NP is 28 micrograms/L before treatment and 49 micrograms/L after 3 months. The laboratory's least significant change for P1NP is 10 micrograms/L. She reports good adherence, has no new bone pain, and her serum calcium and total alkaline phosphatase are normal. What is the most appropriate interpretation of the P1NP result?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Expected anabolic pharmacodynamic response to teriparatide

P1NP reflects type I collagen synthesis and is a marker of osteoblastic bone formation. It has risen by 21 micrograms/L, exceeding the laboratory's least significant change, which is the expected pharmacodynamic response to teriparatide's preferential stimulation of osteoblasts. This supports drug exposure and an anabolic response, although it does not by itself prove fracture-risk reduction or replace clinical and BMD follow-up. Failure of P1NP to rise would prompt review of adherence, injection technique, storage and secondary causes rather than automatically establishing treatment failure. Paget disease and skeletal malignancy cannot be diagnosed from an isolated treatment-associated P1NP rise, particularly with normal alkaline phosphatase and no suggestive symptoms. Increased P1NP is not a toxicity criterion and does not require treatment cessation.

Reference: Hoong CWS, Saul D, Khosla S, Sfeir JG. Advances in the management of osteoporosis—Monitoring therapy and parathyroid hormone-based therapy. BMJ 2025;390:e081250. https://www.medicines.org.uk/emc/product/15421/smpc